Veridon Global is set to bring together leading professionals from the pharmaceutical, biotechnology, healthcare, market access, health economics, and real-world evidence communities for the 3rd Annual Evidence 360: RWE, Market Access & Pricing Summit, taking place on 11–12 March 2027 in Basel, Switzerland.
As healthcare systems continue to place greater emphasis on demonstrating real-world value, generating robust evidence, and achieving sustainable access to innovative therapies, the summit will provide a platform for industry leaders to exchange insights on the evolving role of Real-World Evidence (RWE), market access, pricing, and reimbursement strategies.
RWE Conference 2027: Connecting Evidence With Decision-Making
The RWE conference 2027 comes at a time when healthcare decision-makers are demanding stronger evidence of value.
While randomized controlled trials remain fundamental to demonstrating clinical efficacy, real-world evidence can provide additional insights into how treatments perform across broader and more diverse patient populations in routine clinical practice.
Organizations are increasingly using RWE to address questions surrounding:
- Treatment effectiveness in real-world populations
- Patient outcomes and treatment pathways
- Healthcare resource utilization
- Comparative effectiveness
- Safety and long-term outcomes
- Patient-reported outcomes
- Health economics and healthcare costs
- Value assessment and reimbursement decisions
For pharmaceutical and biotechnology organizations, the ability to generate and communicate credible evidence throughout the product lifecycle can have a significant impact on market access and commercial success.
Real World Evidence Conference Basel 2027
The Real World Evidence Conference Basel 2027 will be particularly relevant for professionals working at the intersection of evidence generation, market access, health economics, pricing, and reimbursement.
Basel is an important European hub for the life sciences industry, making it a natural location for conversations about the future of evidence-based healthcare.
The summit provides an environment for industry professionals to examine how organizations can move from simply collecting real-world data to generating actionable evidence that supports strategic decisions.
The focus is increasingly shifting from data volume to evidence quality, relevance, credibility, and usability.
Market Access Strategies in a Changing Healthcare Environment
Generating strong clinical and real-world evidence is only one part of successfully bringing a healthcare product to market.
Companies must also develop effective market access strategies that demonstrate value to payers, healthcare providers, patients, and other stakeholders. Market access has become increasingly complex as healthcare systems evaluate therapies based on a combination of clinical outcomes, economic impact, unmet medical need, patient value, and budget considerations.
Effective market access strategies can involve:
- Early payer engagement
- Evidence planning
- Health technology assessment preparation
- Value communication
- Stakeholder mapping
- Comparative effectiveness research
- Patient access considerations
- Local market requirements
- Evidence-based value propositions
By integrating RWE into market access planning, organizations can develop a stronger understanding of how therapies deliver value in actual clinical settings.
Pricing and Reimbursement Strategies
Another central consideration for pharmaceutical and biotechnology companies is the development of sustainable pricing and reimbursement strategies.
Pricing decisions increasingly depend on evidence demonstrating the clinical and economic value of a product.
Payers may consider factors such as comparative outcomes, healthcare resource utilization, cost-effectiveness, patient population, treatment alternatives, and overall budget impact.
This makes the relationship between RWE, pricing, and reimbursement increasingly important.
High-quality real-world evidence can help organizations understand treatment outcomes and healthcare utilization while supporting the development of stronger value narratives for payer discussions. At the same time, pricing and reimbursement strategies need to reflect differences between healthcare systems and individual markets.
Bringing RWE, Market Access, Pricing and Reimbursement Together
One of the most important developments in modern life sciences strategy is the convergence of evidence generation and commercial decision-making. RWE should not be viewed as an isolated activity conducted after a product reaches the market. Increasingly, companies are considering evidence requirements throughout the product lifecycle.
A coordinated strategy can connect:
Clinical development → Real-world evidence → Health economics → Market access → Pricing → Reimbursement → Patient outcomes
This integrated approach can help organizations identify evidence gaps earlier and develop strategies that address the needs of multiple stakeholders.
Get in touch with us for more details and secure your place at this leading Real World Evidence Conference in Basel, Switzerland at https://veridonglobal.com/contact/
Looking Ahead to 11–12 March 2027
Taking place on 11–12 March 2027 in Basel, Switzerland, the event arrives at an important point for the global life sciences industry.
As healthcare stakeholders continue to demand greater transparency, stronger evidence, and clearer demonstrations of value, organizations will need to rethink how they generate and use evidence across the product lifecycle.
The RWE conference in Basel, Switzerland will therefore be relevant not only to specialists in real-world evidence but also to professionals involved in market access, pricing, reimbursement, health economics, commercial strategy, clinical research, and healthcare decision-making. For those searching for an RWE conference 2027, REW conference 2027, or Real World Evidence Conference Basel 2027, Veridon Global’s Evidence 360 Summit represents an opportunity to engage with the evolving conversation around evidence-driven healthcare.
